English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Ulcerative colitis (UC) is a chronic and incurable disease characterised by periods of activity and remission. There are several indexes that evaluate the UC activity from clinical, biochemical and endoscopic parameters. The faecal calprotectin is a non-invasive marker for detecting intestinal inflammation in UC patients. A new novel integral disease index (Yamamoto-Furusho index) includes clinical, biochemical, endoscopic and histological findings that evaluate the full spectrum of activity in UC patients. The aim is to correlate the Novel Index Activity index (Yamamoto-Furusho Index) with faecal calprotectin levels in UC patients and compare with other indexes. Methods A total of 158 patients with confirmed diagnosis of UC from the IBD Clinic were recruited in the period between July 2017 and June 2019. All demographic and clinical characteristics were collected from clinical charts. The faecal calprotectin was measured at least 1 week before the colonoscopy and biopsies. The Spearman’s Rho was used for the correlation. A p-value of &amp;lt;0.05 was considered as significant. Results We analysed 185 patients with UC, 85 patients (51.8%) were women and 73 (44.5%) men, with an average current age of 43.53 years (+14.35), an age at diagnosis of 36.6 + 15.1 years and disease duration of 11.27 ± 8.1 years. The extension was distributed on proctitis (E1) in 13.3%, left colitis (E2) in 19.6% and pancolitis (E3) in 31.6%. The treatment was based on mesalazine in 93.9%, steroids in 26.2% and azathioprine in 15.9%. The correlation between faecal calprotectin and the Yamamoto–Furusho index was high (rho = 0.730, p &amp;lt; 0.0001) compared with other indexes such as endoscopic Mayo sub-score (rho = 0.705, p = &amp;lt;0.001); Truelove–Witts (rho = 0.644, p = &amp;lt;0.001), Full Mayo score (rho = 0.708, p = &amp;lt;0.001) and Montreal (rho = 0.551, p = &amp;lt;0.001). Conclusion The novel integral index showed a high correlation with faecal calprotectin compared with other UC indexes for evaluating disease activity in UC patients.

P122 High correlation between faecal calprotectin and a Novel Integral Index for evaluating disease activity in ulcerative colitis patients